Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues

Drug Metabolism and Disposition

Volumn 32, Issue 9, 2004, Pages 1008-1014

  Matheny, Christopher J ^a   Ali, Rabia Y ^a   Yang, Xiaodong ^a   Pollack, Gary M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA CYANOPREGNENOLONE; CYTOCHROME P450 3A; DEXAMETHASONE; GLYCOPROTEIN P; HYPERICUM PERFORATUM EXTRACT; KIRA; NELFINAVIR; NIFEDIPINE; RIFAMPICIN; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG INTERACTION; ENZYME INDUCTION; ENZYME REGULATION; LIVER; MALE; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; TISSUE SPECIFICITY; WESTERN BLOTTING;

ACTINS; ADMINISTRATION, ORAL; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BLOTTING, WESTERN; BRAIN; CYTOCHROME P-450 CYP3A; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; ENZYME INDUCTION; GENE EXPRESSION REGULATION; HYPERICUM; INTESTINE, SMALL; INTUBATION; LIVER; MALE; MICE; MICE, INBRED STRAINS; NIFEDIPINE; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN; PLANT EXTRACTS; PREGNENOLONE CARBONITRILE; PROTEIN ISOFORMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; RIFAMPIN; TAMOXIFEN; TIME FACTORS;

ANIMALIA; HYPERICUM; HYPERICUM PERFORATUM; MURINAE; STAPHYLOCOCCUS PHAGE 3A;

EID: 4143153180     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Aquilante CL, Letrent SP, Pollack GM, and Brouwer KLR (2000) Increased brain P-glycoprotein in morphine tolerant rats. Life Sci 66:47-51.
2. Blumberg B, Sabbagh W Jr, Juguilon H, Bolado J Jr, van Meter CM, Ong ES, and Evans RM (1998) SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 12:3195-3205.
3. Brady JM, Cherrington NJ, Hartley DP, Buist SC, Li N, and Klaassen CD (2002) Tissue distribution and chemical induction of multiple drug resistance genes in rats. Drug Metab Dispos 30:838-844.
4. 2.5] enkephalin by P-glycoprotein modulation. Pharm Res (NY) 16:296-301.
5. Cummins CL, Salphati L, Reid MJ, and Benet LZ (2003) In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J Pharmacol Exp Ther 305:306-314.
6. Dagenais C, Rousselle C, Pollack GM, and Scherrmann JM (2000) Development of an in situ mouse brain perfusion model and its application to mdrla P-glycoprotein-deficient mice. J Cereb Blood Flow Metab 20:381-386.
7. Demeule M, Brossard M, and Beliveau R (1999) Cisplatin induces renal expression of P-glycoprotein and canalicular multispecific organic anion transporter. Am J Physiol 277:F832-840.
8. Dresser GK, Schwarz UI, Wilkinson GR, and Kim RB (2003) Coordinate induction of both cytochrome P4503A and MDR1 by St. John's wort in healthy subjects. Clin Pharmacol Ther 73:41-50.
9. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, and Fattinger K (2000) St. John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68:598-604.
10. Dussault I, Lin M, Hollister K, Wang EH, Synold TW, and Forman BM (2001) Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J Biol Chem 276:33309-33312.
11. Geick A, Eichelbaum M, and Burk O (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581-14587.
12. Gilman AG, Rall TW, Nies AS, and Taylor P (1990) The Pharmacologic Basis of Therapeutics, Pergamon Press, New York.
13. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, and Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Investig 104:147-153.
14. Hebert MF, Fisher RM, Marsh CL, Dressler D, and Bekersky I (1999) Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 39:91-96.
15. Huang L, Wring SA, Woolley JL, Brouwer KR, Serabjit-Singh C, and Polli JW (2001) Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 29:754-760.
16. Jette L, Beaulieu E, Leclerc JM, and Beliveau R (1996) Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am J Physiol 270:F756-765.
17. Johnson BM, Chen W, Borchardt RT, Charman WN, and Porter CJ (2003) A kinetic evaluation of the absorption, efflux and metabolism of verapamil in the autoperfused rat jejunum. J Pharmacol Exp Ther 305:151-158.
18. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM, Zetterstrom RH, et al. (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92:73-82.
19. Labialle S, Gayet L, Marthinet E, Rigal D, and Baggetto LG (2002) Transcriptional regulators of the human multidrug resistance 1 gene: recent views. Biochem Pharmacol 64:943-948.
20. Lee CH (2001) Induction of P-glycoprotein mRNA transcripts by cycloheximide in animal tissues: evidence that class I Pgp is transcriptionally regulated whereas class II Pgp is post-transcriptionally regulated. Mol Cell Biochem 216:103-110.
21. Lee CH, Bradley G, and Ling V (1998) Increased P-glycoprotein messenger RNA stability in rat liver tumors in vivo. J Cell Physiol 177:1-12.
22. Lin JH (2003) Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 55:53-81.
23. Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, and Kliewer SA (2002) Nuclear pregnane X receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 62:638-646.
24. Matheny CJ, Lamb MW, Brouwer KLR, and Pollack GM (2001) Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 21:778-796.
25. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, and Kliewer SA (2000a) St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97:7500-7502.
26. Moore LB, Parks DJ, Jones SA, Bledsoe RK, Consler TG, Stimmel JB, Goodwin B, Liddle C, Blanchard SG, Willson TM, et al. (2000b) Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 275:15122-15127.
27. Morello KC, Wurz GT, and DeGregorio MW (2003) Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 42:361-372.
28. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, and Raunio H (1998) Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 28:1203-1253.
29. Salphati L and Benet LZ (1998) Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers. Biochem Pharmacol 55:387-395.
30. Schinkel AH, Wagenaar E, Mol CA, and van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Investig 97:2517-2524.
31. Schuetz EG, Beck WT, and Schuetz JD (1996a) Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49:311-318.
32. Schuetz EG, Schinkel AH, Relling MV, and Schuetz JD (1996b) P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 93:4001-4005.
33. Seegers U, Potschka H, and Loscher W (2002) Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions. Eur J Pharmacol 451:149-155.
34. Staudinger J, Liu Y, Madan A, Habeebu S, and Klaassen CD (2001) Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab Dispos 29:1467-1472.
35. Synold TW, Dussault I, and Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7:584-590.
36. Tirona RG, Lee W, Leake BF, Lan LB, Cline CB, Lamba V, Parviz F, Duncan SA, Inoue Y, Gonzalez FJ, et al. (2003) The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 9:220-224.
37. Wacher VJ, Wu CY, and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134.
38. Yanagimoto T, Itoh S, Sawada M, and Kamataki T (1997) Mouse cytochrome P450 (Cyp3aII): predominant expression in liver and capacity to activate aflatoxin B1. Arch Biochem Biophys 340:215-218.
39. Zhang JN, Liu XG, Zhu M, Chiu FC, and Li RC (1998) Assessment of presystemic factors on the oral bioavailability of rifampicin following multiple dosing. J Chemother 10:354-359.
40. Zong J and Pollack GM (2003) Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin. J Pharmacol Exp Ther 306:556-562.